Which of the following disease states have established Healthcare Effectiveness Data and Information Set (HEDIS) measures for comparing institutional performance: peripheral arterial disease, heart failure, chronic kidney disease, or hypertension?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 24, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

HEDIS Measures: Heart Failure and Hypertension

Based on the ACCF/AHA Task Force documentation, HEDIS measures have been established for both heart failure and hypertension, making these the disease states with validated national benchmarks for institutional performance comparison 1.

Disease States with Established HEDIS Measures

Heart Failure

  • Inpatient measures developed by ACC/AHA in 2005, currently undergoing updates 1
  • Outpatient measures developed by ACC/AHA/PCPI in 2005, also undergoing updates 1
  • These measures are designated as "performance measures" appropriate for both quality improvement and external reporting 1

Hypertension

  • Original measures published in 2005 by ACC/AHA/PCPI 1
  • Updated in 2011, making them among the most current validated measures 1
  • Validated for institutional performance comparison and external reporting 1
  • Research demonstrates that blood pressure control measures have the largest potential effect on quality at the national level, with potential to prevent millions of cardiovascular events 2

Disease States WITHOUT Established HEDIS Measures

Peripheral Arterial Disease

  • Performance measures exist but are NOT HEDIS measures 3
  • The ACCF/AHA developed PAD-specific performance measures in 2010 3
  • These are categorized as either "performance measures" (suitable for external reporting) or "quality measures" (for quality improvement only, requiring further validation) 3
  • Critical distinction: These are ACCF/AHA performance measures, not HEDIS measures used for national benchmarking 1

Chronic Kidney Disease

  • No established HEDIS measures identified in the evidence
  • While CKD is frequently studied in conjunction with other conditions (PAD, heart failure, hypertension) 4, 5, 6, no standalone HEDIS measures for CKD institutional comparison exist
  • CKD appears as a comorbidity in other disease-specific measures but lacks its own HEDIS framework

Key Clinical Context

The distinction between HEDIS measures and other performance measures is crucial:

  • HEDIS measures are standardized by the National Committee for Quality Assurance (NCQA) and used across health plans for national benchmarking 7
  • ACCF/AHA performance measures are specialty-specific tools that may or may not be suitable for external reporting 1, 3
  • Only measures validated through extensive field testing and shown appropriate for accountability purposes qualify as true HEDIS measures 1

Common Pitfall

Do not confuse the existence of performance measures (which exist for PAD) with HEDIS measures specifically designed for institutional comparison against national benchmarks. The evidence clearly shows PAD has ACCF/AHA performance measures but these are distinct from HEDIS measures 1, 3.

Answer: Heart failure and hypertension have established HEDIS measures for institutional performance comparison.

References

7
Research

Agreement Between HEDIS Performance Assessments in the VA and Medicare Advantage: Is Quality in the Eye of the Beholder?

Inquiry : a journal of medical care organization, provision and financing, 2016

Related Questions

Which antihypertensive drug classes are recommended for specific clinical scenarios such as diabetes mellitus or chronic kidney disease with proteinuria, heart failure or post‑myocardial infarction, patients of African descent or with isolated systolic hypertension, pregnant women, elderly patients, and those with resistant hypertension?
What is the best oral antidiabetic agent for a patient with heart failure, coronary artery disease, stage 3b chronic kidney disease (estimated glomerular filtration rate 30–44 mL/min), and hypertension?
What is the recommended starting dose, titration schedule, monitoring parameters, and contraindications for captopril in an adult with hypertension or heart failure (including diabetic nephropathy)?
What are the potential causes and management strategies for lower limb pain in patients with Chronic Kidney Disease (CKD)?
What is the definition of comorbidities (co-existing medical conditions)?
Can an adult safely take two hydrocodone 10 mg tablets at once?
Which individual has authority to declare a public health emergency that permits the use of unapproved medical products, such as COVID‑19 vaccines?
Why must patients fast for 2–4 hours before a cardiac stress test?
Does Zepbound (tirzepatide) have pharmacokinetic or pharmacodynamic interactions with flecainide, metoprolol, lisinopril, rosuvastatin, montelukast, diltiazem, or fenofibrate?
In an adult with type 2 diabetes initiating metformin therapy, how long does it take for fasting blood glucose to begin decreasing?
In a 71-year-old, 50-kg female with anxiety, depression, and hypertension who is found unconscious with hypotension, bradycardia, and a widened QRS interval after an overdose of metoprolol succinate and amlodipine, which initial therapy should be given in addition to an intravenous norepinephrine infusion?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.